We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




POC Test Identifies and Differentiates Viral from Bacterial Acute Respiratory Infection in 10 Minutes

By LabMedica International staff writers
Posted on 22 Jun 2022

Clinical diagnosis of patients with viral and bacterial acute respiratory infection can be a challenge due to similar signs and symptoms. More...

An acute respiratory infection, typically presenting as cough, cold, sore throat, and runny nose, is the most common single reason for visiting a doctor and antibiotic prescriptions. However, most coughs, colds, sore throats, runny noses and earaches are caused by viruses and do not require antibiotics. Accurate detection of a viral infection can help prioritize which patients should have pathogen-specific testing performed. Now, a rapid test to differentiate a viral from a bacterial infection may lead to a considerable reduction in unnecessary antibiotics, which could lead to a reduction in antimicrobial resistance and adverse events.

FebriDx from Lumos Diagnostics (Melbourne, Australia) is a rapid, all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. FebriDx can be used to help in decision making at the point of care to reduce uncertainty, avoid unnecessary antibiotics, and enable appropriate patient management. It can assist with a diagnosis in 10 minutes for patients with acute respiratory infections. The FebriDx test is easily performed by a nurse or healthcare worker to help with decision making and freeing up valuable physician time. FebriDx can aid in determining whether a patient needs antibiotics within a single clinic visit.

In multi-center U.S. clinical trials to evaluate the diagnostic accuracy of FebriDx in distinguishing between bacterial and viral acute respiratory infections, the test was determined to have both high sensitivity (up to 95%) to detect a bacterial infection and up to 99% negative predictive value (NPV) to safely rule out a bacterial infection. Additionally, an economic evaluation has concluded that using the FebriDx test to guide antibiotic treatment for patients presenting with acute respiratory infections could potentially result in USD 2.5 billion of annual cost saving for the U.S. healthcare system.

Related Links:
Lumos Diagnostics 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.